

Supporting Information

Synthesis and Antimicrobial Activity of Novel 4-Hydroxy-2-quinolone Analogues

Thitiphong Khamkhenshorngphanuch ^{1,†}, Kittipat Kulkraisri ^{2,†}, Alongkorn Janjamratsaeng ^{2,†},
Napasawan Plabutong ³, Arsa Thammahong ³, Kanitta Manadee ⁴, Sarisa Na Pombejra ⁴, and
Tanatorn Khotavivattana ^{5,*}

¹ Department of General Education, Faculty of Science and Health Technology, Navamindradhiraj University, Bangkok 10300, Thailand; thitiphong.kha@nmu.ac.th

² Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand; kittipatkulkraisri@gmail.com (K.K.); mekans89@gmail.com (A.J.)

³ Antimicrobial Resistance and Stewardship Research Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; fah34405@gmail.com (N.P.); arsa.t@chula.ac.th (A.T.)

⁴ Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand; noonkanitta@gmail.com (K.M.); sarisa.n@chula.ac.th (S.N.)

⁵ Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand

* Correspondence: tanatorn.k@chula.ac.th; Tel.: +66-2-218-7621

† These authors contributed equally to this work.

Content



1. NMR and HRMS spectra	S2
1.1 NMR spectra of 1a-1g	S2
1.2 NMR spectra of 2a-2b	S9
1.3 NMR and HRMS spectra of 3a-3j, 4d and 5d	S11
2. Antimicrobial Activity and Structure-Activity Relationship.....	S34
2.1 The resazurin microdilution assay to determine MICs of the synthesized quinolones against <i>S. aureus</i>	S34
2.2 The MBC results of 3i and 3j against <i>S. aureus</i>	S37
2.3 The resazurin microdilution assay to determine MICs of the synthesized quinolones against <i>E. coli</i>	S38

1. NMR and HRMS spectra



1.1. NMR spectra of 1a – 1g

1-Methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (1a)



Dec24-2018-tkh001
AK-A04-P1
chula_proton8




¹H NMR (400 MHz, DMSO-*d*₆) 8.01 (d, *J* = 7.7 Hz, 1H), 7.86 (d, *J* = 7.9 Hz, 1H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.34 (d, *J* = 7.6 Hz, 1H), 3.47 (s, 3H).



Dec24-2018-tkh001
AK-A04-P1
chula_carbon1k




¹³C NMR (101 MHz, DMSO-*d*₆) 158.95 (s), 147.71 (s), 142.18 (s), 137.15 (s), 129.28 (s), 123.54 (s), 114.80 (s), 111.49 (s), 31.63 (s).




6-Methoxy-1-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (**1b**)


Jun13-2019-tkh003
KKAJ-A13-P1




¹H NMR (400 MHz, DMSO-*d*₆) 7.52 – 7.35 (m, 1H), 3.83 (s, 3H), 3.45 (s, 3H).



Jun13-2019-tkh003
KKAJ-A13-P1




¹³C NMR (101 MHz, DMSO-*d*₆) 158.84 (s), 155.17 (s), 147.52 (s), 136.31 (s), 124.99 (s), 116.54 (s), 112.12 (s), 110.88 (s), 55.80 (s), 31.71 (s).




7-Chloro-1-methyl-2H-benzo[d][1,3]oxazine-2,4 (1H)-dione (**1c**)


Jun27-2019-tkh008
KKAJ-A20-P1




¹H NMR (400 MHz, DMSO)
8.00 (d, $dJ = 8.4$ Hz, 1H), 7.58 (s, 1H), 7.39 (d, $dJ = 8.3$ Hz, 1H), 3.46 (s, 3H).



Jun27-2019-tkh008
KKAJ-A20-P1




¹³C NMR (101 MHz, DMSO) 158.27 (s), 143.39 (s), 141.89 (s), 131.01 (s), 123.64 (s), 114.86 (s), 110.59 (s), 31.91 (s).




1-Methyl-7-nitro-2H-benzo[d][1,3] oxazine-2,4(1H)-dione (**1d**)


Jun24-2019-tkh002
KKAJ-A14-P1




¹H NMR (400 MHz, DMSO-*d*₆) 8.25 (d, *J* = 8.5 Hz, 1H), 8.12 (d, *J* = 1.5 Hz, 1H), 8.06 (dd, *J* = 8.5, 1.8 Hz, 1H), 3.56 (s, 3H).



Jun19-2019-tkh003
KKAJ-A14-C1




¹³C NMR (101 MHz, DMSO-*d*₆) 157.87 (s), 152.43 (s), 147.33 (s), 143.06 (s), 131.13 (s), 117.50 (s), 110.82 (s), 109.84 (s), 32.08 (s).




6-Chloro-1-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (**1e**)


Jul22-2019-tkh003
KKAJ-A27-P1




¹H NMR (400 MHz, CDCl₃)
8.22 (d, *J* = 2.4 Hz, 1H), 7.82 (dd, *J* = 8.9, 2.5 Hz, 1H), 7.36 (s, 1H), 3.68 (s, 3H).



Jul22-2019-tkh003
KKAJ-A27-P1




¹³C NMR (101 MHz, CDCl₃) 157.30 (s), 147.59 (s), 141.17 (s), 140.19 (s), 133.20 (s), 115.80 (s), 113.42 (s), 32.17 (s).




6-Bromo-1-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (**1f**)


Aug09-2019-tkh002
KKAJ-A30-P1




^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, $J = 2.3$ Hz, 1H), 7.85 (dd, $J = 8.8, 2.3$ Hz, 1H), 7.08 (d, $J = 8.9$ Hz, 1H), 3.57 (s, 1H).



Desktop




^{13}C NMR (101 MHz, CDCl_3) δ 157.31 (s), 147.59 (s), 141.17 (s), 140.19 (s), 133.20 (s), 117.06 (s), 115.80 (s), 113.42 (s), 32.17 (s).




1-Ethyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (**1g**)


Jul31-2019-tkh001
KKAJ-A33-P1




^1H NMR (400 MHz, DMSO- d_6) 8.02 (d, $J = 7.8$ Hz, 1H), 7.85 (t, $J = 7.9$ Hz, 1H), 7.50 (d, $J = 8.5$ Hz, 1H), 7.33 (t, $J = 7.6$ Hz, 1H), 4.06 (q, $J = 7.0$ Hz, 1H), 1.23 (t, $J = 7.1$ Hz, 1H).




Jul31-2019-tkh001
KKAJ-A33-P1




^{13}C NMR (101 MHz, DMSO- d_6) 141.11 (s), 137.23 (s), 129.61 (s), 123.47 (s), 114.58 (s), 111.75 (s), 11.86 (s).




Jan13-2019-tkh002
TK-C60-P2
chula_proton32




¹H NMR (400 MHz, CDCl₃) δ 4.19 (q, *J* = 7.1 Hz, 2H), 3.42 (s, 2H), 2.52 (t, *J* = 7.4 Hz, 2H), 1.65–1.52 (m, 3H), 1.24 (s, 20H), 0.89–0.85 (m, *J* = 6.6 Hz, 5H).




Jan13-2019-tkh002
TK-C60-P2
chula_carbon1k




¹³C NMR (101 MHz, CDCl₃) δ 203.11 (s), 167.43 (s), 89.09 (s), 61.46 (s), 60.02 (s), 49.45 (s), 43.19 (s), 35.20 (s), 33.97 (s), 32.05 (s), 29.80 (s), 29.77 (s), 29.72 (s), 29.57 (s), 29.48 (s), 29.37 (s), 29.21 (s), 29.17 (s), 26.40 (s), 24.86 (s), 23.63 (s), 22.81 (s), 14.22 (s).




Oct02-2019-tkh002
KKAJ-A48-P1




¹H NMR (400 MHz, CDCl₃) δ 4.19 (q, *J* = 7.1 Hz, 1H), 3.42 (s, 1H), 2.52 (t, *J* = 7.4 Hz, 1H), 1.60 (dd, *J* = 21.9, 14.9 Hz, 1H), 1.45–1.16 (m, 4H), 0.87 (t, *J* = 6.7 Hz, 1H).



Oct02-2019-tkh002
KKAJ-A48-P1




¹³C NMR (101 MHz, CDCl₃) δ 61.45, 49.45, 43.18, 35.20, 31.99, 29.53, 29.48, 29.37, 29.19, 29.16, 26.39, 23.62, 22.78, 14.23



1.3 NMR and HM spectra of 3a-3j, 4d and 5d

4-Hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3a)




Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\190819\A16_RB6_01_2960.d
Method nv_pos_6min_profile_wguardcol_190624.m
Sample Name A16
Comment


Acquisition Date 8/19/2019 7:31:14 PM

Operator CU.
Instrument microTOF-Q II




4-Hydroxy-6-methoxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (**3b**)

Jun25-2019-tkh001
KKAJ-A17-P1



Jun19-2019-tkh002
KKAJ-A15-P1




Generic Display Report

Analysis Info



Analysis Name D:\Data\Data Service\190819\A17_RB5_01_2959.d
Method nv_pos_6min_profile_wguardcol_190624.m
Sample Name A17
Comment

Acquisition Date 8/19/2019 7:24:49 PM

Operator CU.
Instrument micrOTOF-Q II



7-Chloro-4-hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (3c)




Generic Display Report

Analysis Info



Analysis Name D:\Data\Data Service\190819\A24_RB7_01_2965.d
Method nv_neg_6min_profile_wguardcol_190624.m
Sample Name A24
Comment

Acquisition Date 8/19/2019 8:05:53 PM

Operator CU.
Instrument microTOF-Q II



4-Hydroxy-1-methyl-7-nitro-3-tetradecanoylquinolin-2(1H)-one (3d)




Generic Display Report

Analysis Info



Analysis Name D:\Data\Data Service\190827\A25-P3_RA8_01_3015.d
Method nv_neg_6min_profile_wguardcol_190624.m
Sample Name A25-P3
Comment

Acquisition Date 8/27/2019 9:10:35 PM

Operator CU.
Instrument micrOTOF-Q II



Ethyl 1-methyl-7-nitro-4-oxo-2-tridecyl-1,4-dihydroquinoline-3-carboxylate (**4d**)




Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\190819\A25-P4_RB4_01_2958.d
Method nv_pos_6min_profile_wguardcol_190624.m
Sample Name A25-P4
Comment


Acquisition Date 8/19/2019 7:18:29 PM

Operator CU.
Instrument micrOTOF-Q II




2-(methylamino)-4-nitrobenzoic acid (**5d**)


Jun27-2019-tkh007
KKAJ-A18-P3




¹H NMR (400 MHz, DMSO-d₆) 7.99 (d, *J* = 8.6 Hz, 1H), 7.37 (d, *J* = 1.7 Hz, 1H), 7.33 – 7.27 (m, 1H), 3.46 (s, 1H), 2.91 (s, 3H).



Jun27-2019-tkh007
KKAJ-A18-P3




¹³C NMR (101 MHz, DMSO-d₆)
168.63 (s), 151.78 (s), 151.39 (s),
133.26 (s), 115.08 (s), 107.65 (s),
104.81 (s), 29.32 (s).




6-Chloro-4-hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (**3e**)


Jul22-2019-tkh002
KKAJ-A28-P1




¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 2.4 Hz, 1H), 7.65 (dd, *J* = 9.0, 2.5 Hz, 1H), 7.29 (dd, *J* = 3.2 Hz, 1H), 3.66 (s, 3H), 3.31 (d, *J* = 7.4 Hz, 2H), 1.73 (d, *J* = 14.9, 7.5 Hz, 2H), 1.64 (s, 2H), 1.42 (d, *J* = 8.8 Hz, 2H), 1.28 (s, 16H), 0.91 (t, *J* = 6.8 Hz, 3H).



Jul22-2019-tkh002
KKAJ-A28-P1



¹³C NMR (101 MHz, CDCl₃) δ 209.44 – 208.88 (m), 172.98 (s), 162.27 – 159.96 (m), 140.04 – 138.76 (m), 134.69 (s), 125.40 (s), 125.40 (s), 115.70 (s), 115.70 (s), 43.46 – 42.18 (m), 32.38 – 31.35 (m), 30.39 – 26.57 (m), 24.33 – 22.82 (m), 22.82 – 21.79 (m), 14.21 – 13.50 (m).




Generic Display Report

Analysis Info



Analysis Name D:\Data\Data Service\190819\A28_RB8_01_2967.d
Method nv_neg_6min_profile_wguardcol_190624.m
Sample Name A28
Comment

Acquisition Date 8/19/2019 8:18:49 PM

Operator CU.
Instrument micrOTOF-Q II



6-Bromo-4-hydroxy-1-methyl-3-tetradecanoylquinolin-2(1H)-one (**3f**)




Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\190819\A31_RC2_01_2969.d
Method nv_neg_6min_profile_wguardcol_190624.m
Sample Name A31
Comment


Acquisition Date 8/19/2019 8:31:48 PM

Operator CU.
Instrument micrOTOF-Q II




1-Ethyl-4-hydroxy-3-tetradecanoylquinolin-2(1H)-one (3g)


Sep04-2019-tkh002
KKAJ-A36-P2




¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.71 – 7.65 (m, 1H), 7.34 – 7.26 (m, 1H), 7.23 (d, *d* = 7.3 Hz, 1H), 4.35 – 4.26 (m, 2H), 3.33 – 3.27 (m, 2H), 1.77 – 1.67 (m, 3H), 1.46 – 1.16 (m, 32H), 0.87 (t, *d* = 6.8 Hz, 3H).



Sep04-2019-tkh002
KKAJ-A36-P2



¹³C NMR (101 MHz, CDCl₃) δ 209.71 (s), 174.07 (s), 161.16 (s), 140.88 (s), 134.83 (s), 133.69 (s), 126.53 (s), 123.77 (s), 121.92 (s), 116.00 (s), 114.14 (s), 105.95 (s), 43.16 (s), 37.22 (s), 32.07 (s), 29.51 (s), 29.50 (s), 24.41 (s), 14.24 (s), 12.94 (s).



BIORESOURCES RESEARCH UNIT

High resolution report

Analysis Name D:\Data\customer\TK3g.d
Method NaFormate_pos.m
Sample Name TK3g

Acquisition Date 6/1/2020 10:30:54 AM


Operator Sutichai Ext: 3560
Instrument micrOTOF Bruker
Calibrate by Sodium Formate

Acquisition Parameter

Source Type ESI
Focus Not active
Scan Begin 100 m/z
Scan End 2000 m/z


Ion Polarity Positive
Set Capillary 4500 V
Set End Plate Offset -500 V

Set Nebulizer 0.3 Bar
Set Dry Heater 180 °C
Set Dry Gas 4.0 l/min
Set Divert Valve Source




3-Decanoyl-4-hydroxy-1-methylquinolin-2(1H)-one (**3h**)


2019-11-04-sja004-KKAJ-A50-P1




NMR (500 MHz, δ 8.24 – 8.15 (m), 7.65 (d, J = 7.1 Hz), 7.23 (dd, J = 16.2, 8.1 Hz), 3.62 (dd, J = 15.7, 1.4 Hz), 3.25 (d, J = 7.0 Hz), 1.68 (d, J = 6.2 Hz), 1.44 – 1.13 (m, J = 57.2 Hz), 0.85 (d, J = 6.1 Hz).



2019-11-04-sja004-KKAJ-A50-P1



NMR (126 MHz, δ 209.66 (s), 174.20 (s), 161.60 (s), 141.71 (s), 134.90 (s), 126.27 (s), 121.93 – 121.48 (m), 115.74 (s), 114.28 (s), 105.91 (s), 43.13 (s), 32.02 (d, J = 13 Hz), 29.98 – 29.00 (m), 24.42 (s), 22.60 – 21.85 (m), 14.25 (s).



BIORESOURCES RESEARCH UNIT

High resolution report


Analysis Name D:\Data\customer\TK 3h.d
 Method NaFormate_pos.m
 Sample Name TK 3h

Acquisition Date 6/1/2020 3:03:32 PM



Operator Sutichai Ext: 3560
 Instrument micrOTOF Bruker
 Calibrate by Sodium Formate

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	100 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	2000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Source



6-Chloro-3-decanoyl-4-hydroxy-1-methylquinolin-2(1H)-one (3i)



BIORESOURCES RESEARCH UNIT

High resolution report


Analysis Name D:\Data\customer\TK 3i.d
 Method NaFormate_pos.m
 Sample Name TK 3i

Acquisition Date 6/1/2020 3:14:55 PM

Operator Sutichai Ext: 3560
 Instrument micrOTOF Bruker
 Calibrate by Sodium Formate


Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	100 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	2000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Source




6-Bromo-3-decanoyl-4-hydroxy-1-methylquinolin-2(1H)-one (**3j**)


2019-11-04-sja005-KKAJ-A51-P1




NMR (500 MHz, δ) 8.40 (d, J = 15.5 Hz), 7.81 (d, J = 8.6 Hz), 7.27 – 7.20 (m), 3.69 (d, 15.0 Hz), 3.33 (d, J = 7.4 Hz), 1.78 (d, J = 5.8 Hz), 1.51 – 1.25 (m), 0.94 (t, 6.8 Hz).



2019-11-04-sja005-KKAJ-A51-P1



NMR (126 MHz, δ) 209.72 (s), 173.46 – 172.94 (m), 162.47 – 160.58 (m), 140.57 (s), 137.57 (s), 128.60 (s), 117.24 (s), 116.09 (s), 115.18 (s), 106.26 (s), 43.14 (s), 32.04 (s), 29.55 (d, 14.6 Hz), 22.82 (s), 20.92 (s), 14.24 (s).



BIORESOURCES RESEARCH UNIT

High resolution report


Analysis Name D:\Data\customer\TK 3j.d
Method NaFormate_pos.m
Sample Name TK 3j

Acquisition Date 6/1/2020 3:26:20 PM

Operator Sutichai Ext: 3560
Instrument micrOTOF Bruker
Calibrate by Sodium Formate

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	100 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	2000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Source



2. Antimicrobial Activity and Structure-Activity Relationship

2.1 The resazurin microdilution assay to determine MICs of the synthesized quinolones against *S. aureus*.

The synthesized compounds (**3a**, **3b**, **3c**, **3d**, **3e**, **3f**, **3g**, **3h**, **3i**, **3j**, and **4d**) were incubated with *S. aureus* (ATCC 6538P) at the final compound concentrations of 1000, 500, 250, 125, 62.5, and 31.25 $\mu\text{g/mL}$. The 4% DMSO in MHB, 4% DMSO in MHB plus *S. aureus*, and ciprofloxacin were used as experimental controls. MIC was defined as a minimum concentration of agents that inhibited the growth of bacteria observed by remaining blue color of resazurin.

The MICs of compound **3i** (*) and **3j** (**) were unclear. However, the **3i** and **3j** seemed to display partial inhibitory effect against *S. aureus* at the concentration between 125-1000 $\mu\text{g/mL}$ and 125-500 $\mu\text{g/mL}$, respectively.




Figure S1. MIC determination of Ciprofloxacin against *S. aureus*.




Figure S2. MIC determination of **3a–3h** against *S. aureus*.




Figure S3. MIC determination of **3i**, **3j** and **4d** against *S. aureus*.

2.2 The MBC results of 3i and 3j against *S. aureus*.

Although 3i and 3j showed inhibitory activity against *S. aureus*, both compounds failed to kill the bacteria confirmed by the presence of bacterial colonies on nutrient agar plates.

Compound




Figure S4. MBC determination of **3i** and **3j** against *S. aureus*.

2.3 The resazurin microdilution assay to determine MICs of the synthesized quinolones against *E. coli*.

The synthesized compounds (**3a**, **3b**, **3c**, **3d**, **3e**, **3f**, **3g**, **3h**, **3i**, **3j**, and **4d**) were incubated with *E. coli* (ATCC 25922) at the final compound concentrations of 1000, 500, 250, 125, 62.5, and 31.25 $\mu\text{g/mL}$. The 4% DMSO in MHB, 4% DMSO in MHB plus *E. coli*, and ciprofloxacin were used as experimental controls. MIC was defined as a minimum concentration of agents that inhibited the growth of bacteria observed by remaining blue color of resazurin.




Figure S5. MIC determination of Ciprofloxacin against *E. coli*.




Figure S6. MIC determination of **3a–3h** Ciprofloxacin against *E. coli*.




Figure S7. MIC determination of **3i**, **3j** and **4d** against *E. coli*.